Market Place
Sourcing Support
Favorable Ovarian Cancer Results at Gynecological Conference
13 Apr 2026 //
GLOBENEWSWIRE
LIXTE Biotechnology Files 2025 Annual Report, Highlights Year
31 Mar 2026 //
GLOBENEWSWIRE
De La Soul`s Good Health Summit Feb. 19 at Morehouse College
21 Jan 2026 //
GLOBENEWSWIRE
LIXTE Biotech to Attend DealFlow Conference Jan. 28-29
20 Jan 2026 //
GLOBENEWSWIRE
LIXTE And Collaborators Expand Clear Cell Ovarian Cancer Trial
23 Dec 2025 //
GLOBENEWSWIRE
Lixte Bio Announces $4.3M Direct Offering Under Nasdaq Rules
18 Dec 2025 //
GLOBENEWSWIRE
Focuses On Oncology Platform With Complementary Modalities
08 Dec 2025 //
PHARMIWEB
LIXTE Steps Into A Key Role In The Rise Of Treatment Amplifiers
03 Dec 2025 //
PHARMIWEB
LIXTE Levels Up From PP2A Innovation To Multi-Modal Oncology
03 Dec 2025 //
PHARMIWEB
LIXTE Bio Acquires Liora`s Proton Therapy For Cancer
25 Nov 2025 //
GLOBENEWSWIRE
Lixte Bio to Present at Spartan Capital Investor Conference 2025
29 Oct 2025 //
GLOBENEWSWIRE
LIXTE Focuses On Lead Candidate LB-100, Advancement Development
16 Oct 2025 //
GLOBENEWSWIRE
Lixte Unveils Plan to Redefine Cancer`s Master Switch on Nasdaq
16 Sep 2025 //
ACCESSWIRE
Lixte Bio`s Summer Sees Leadership Updates, Scientific Progress
15 Sep 2025 //
PHARMAWEB
LIXTE Buy $2.6M Digital Currency for Diversification, Acquisition
10 Sep 2025 //
GLOBENEWSWIRE
Lixte Targets Unmet Oncology Markets with New Strategy
25 Aug 2025 //
GLOBENEWSWIRE
LIXTE Biotech`s LB-100 Strategy Revisited by 24/7 Market News
19 Aug 2025 //
GLOBENEWSWIRE
Lixte Biotechnology Holdings Provides Corporate Update
18 Aug 2025 //
GLOBENEWSWIRE
LIXTE Biotech to Report Phase 1B/2 Trial Results in 2H 2025
14 Aug 2025 //
GLOBENEWSWIRE
LIXTE Biotech Updates Treasury Policy to Include Cryptocurrency
13 Aug 2025 //
GLOBENEWSWIRE
LIXTE Biotech Adds Cryptocurrency to Treasury Management Strategy
13 Aug 2025 //
GLOBENEWSWIRE
LIXTE Biotech Holdings Meets Nasdaq`s Listing Requirements Again
16 Jul 2025 //
GLOBENEWSWIRE
Scientific Journal Nature Validates LIXTE`s Ovarian Cancer Trials
09 Jul 2025 //
GLOBENEWSWIRE
Lixte Biotech Closes $1.5 Million Registered Direct Offering
08 Jul 2025 //
GLOBENEWSWIRE
Lixte Biotechnology Holdings Closes $5.0M Private Placement
02 Jul 2025 //
GLOBENEWSWIRE
Lixte Biotech Secures $5M in Private Placement Funding
01 Jul 2025 //
GLOBENEWSWIRE
Lixte Starts Study On LB-100 For Pre-Cancerous Cell Removal
31 Mar 2025 //
GLOBENEWSWIRE
LIXTE Biotechnology Updates Progress on LB-100 for Cancer
27 Mar 2025 //
GLOBENEWSWIRE
New Findings Show how LIXTE™s Lead Clinical Compound, LB-100
10 Mar 2025 //
GLOBENEWSWIRE
LIXTE Bio Closes $1.05M Registered Offering Priced At-the-Market
13 Feb 2025 //
GLOBENEWSWIRE
LIXTE Biotechnology Announces $1.05M Registered Offering
11 Feb 2025 //
GLOBENEWSWIRE
LIXTE Bio Submits Request for Withdrawal of Form S-1 Registration
10 Feb 2025 //
GLOBENEWSWIRE
LIXTE Receives U.S. Patent Issue Notification for Immune Oncology
04 Sep 2024 //
GLOBENEWSWIRE
LIXTE Doses First Patient in Trial for Colorectal Cancer with Pharma Support
26 Aug 2024 //
GLOBENEWSWIRE
First Patient Dosed With LIXTE`s LB-100 In New Colorectal Cancer Trial
26 Aug 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Provides Update On Recent Activities and Developments
19 Aug 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Holdings to Present at Two Investor Conferences
15 Aug 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Holdings Provides Update on Recent Activities
20 May 2024 //
GLOBENEWSWIRE
First Patient Dosed with LIXTE`s LB-100 and GSK`s Immunotherapy Dostarlimab-gxly
29 Jan 2024 //
GLOBENEWSWIRE
LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering
18 Jul 2023 //
GLOBENEWSWIRE
LIXTE BiotechnologyRegains Compliance with Nasdaq Continued Listing
23 Jun 2023 //
GLOBENEWSWIRE
Lixte Biotechnology Holdings Reports That Its Lead Clinical Compound, Lb-100
07 Feb 2023 //
GLOBENEWSWIRE
